心玮医疗-B(06609)尾盘涨近7%,上半年实现扭亏为盈,净利润达5090万元。公司营业收入同比增长44.4%至1.86亿元,主要得益于出血性产品和缺血性产品矩阵的持续迭代与量化贡献。心玮医疗在研产销一体化闭环方面取得显著进展,目前已获得32款器械产品的NMPA批准、三款器械产品的FDA批准及一款产品的CE标志,产品管线涵盖急性缺血性脑卒中、神经血管狭窄治疗、缺血性脑卒中预防、出血性脑卒中治疗...
Source Link心玮医疗-B(06609)尾盘涨近7%,上半年实现扭亏为盈,净利润达5090万元。公司营业收入同比增长44.4%至1.86亿元,主要得益于出血性产品和缺血性产品矩阵的持续迭代与量化贡献。心玮医疗在研产销一体化闭环方面取得显著进展,目前已获得32款器械产品的NMPA批准、三款器械产品的FDA批准及一款产品的CE标志,产品管线涵盖急性缺血性脑卒中、神经血管狭窄治疗、缺血性脑卒中预防、出血性脑卒中治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.